Clinical Trial Update: Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating deferasirox for very low/low/intermediate-risk transfusion-dependent anemia and myelodysplastic syndrome was terminated; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndrome

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Anemia, Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2020-07-01